A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2018) | Viewed by 93746
Interests: neuro-oncology; glioblastoma; meningioma; oncolytic virus; herpes simplex virus; gene therapy
Special Issues, Collections and Topics in MDPI journals
Oncolytic viruses (OV) are either genetically-engineered or naturally-occurring viruses that exploit defective anti-viral immune response in cancer cells for therapeutic gain. OV selectively replicate and destroy neoplastic cells, while sparing normal cells, leading to release of tumor antigens and induction of adaptive anti-tumor cellular immune response, which is now considered a critical mechanism-of-action (MOA). The multipronged MOA is indeed unique for OV and attributable to both potentially durable response and activity for otherwise refractory anti-apoptotic cancer.
After decades of early developmental stage of OV, the field has finally entered an exciting time; in late 2015 talimogene laherparepvec became the first FDA-approved OV for the treatment of advanced melanoma. Subsequent clinical trial testing talimogene laherparepvec and immune checkpoint inhibitor is reported to show clinical benefits of combining the two modalities in metastatic melanoma patients. These milestones are boosting extensive efforts from both academia and industry to develop OVs from a number of different virus families with the tangible goal to commercialize them as new cancer drugs.
There, perhaps, has never been a better time for us to ponder how to best harness preclinical research to meaningfully advance the field of OV. Clinically relevant questions still abound; selection of virus species for a particular patient or cancer type, modification of immune response against virus and tumor to maximize potency, optimization of delivery and dosing schedule for a given OV, use of appropriate animal model, etc. Laboratory research should be able to approach to some if not all to provide scientific basis and rationales to guide designing clinical trials that have increased likelihood of success. This Special Issue will discuss the cutting-edge research of OV, with a particular emphasis on the role that bench and animal model investigations could play towards ultimately improving management of cancer.
Dr. Hiroaki Wakimoto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.